Rapid Study on Mefloquine Hydrochloride Complexation with Hydroxypropyl-β-Cyclodextrin and Randomly Methylated β-Cyclodextrin: Phase Diagrams, Nuclear Magnetic Resonance Analysis, and Stability Assessment.

cyclodextrins drug stability inclusion complexes mefloquine nuclear magnetic resonance spectroscopy stereoisomerism

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
18 Dec 2023
Historique:
received: 19 10 2023
revised: 04 12 2023
accepted: 13 12 2023
medline: 23 12 2023
pubmed: 23 12 2023
entrez: 23 12 2023
Statut: epublish

Résumé

This study investigates the complexation of mefloquine hydrochloride by cyclodextrins to improve its solubility in order to design an oral solution. This approach may enhance the effectiveness of mefloquine, a drug which can be used for malaria prophylaxis and treatment in children. Mefloquine hydrochloride's solubility was assessed in different buffer solutions, and its quantification was achieved through high-performance liquid chromatography. The complexation efficiency with cyclodextrins was evaluated, and nuclear magnetic resonance (NMR) methods were employed to determine the interactions between mefloquine and cyclodextrins. Mefloquine's solubility increased when combined with hydroxypropyl-β-cyclodextrin (HP-β-CD) and randomly methylated β-cyclodextrin (RAMEB), with RAMEB being more effective. The drug's solubility varied across different pH buffers, being higher in acidic buffers. Interestingly, mefloquine's solubility decreased with a citrate buffer, possibly due to precipitation. The NMR studies highlighted non-covalent interactions between RAMEB, HP-β-CD, and mefloquine, explaining the solubilizing effect via complexation phenomena. Furthermore, the NMR experiments indicated the complexation of mefloquine by all the studied cyclodextrins, forming diastereoisomeric complexes. Cyclodextrin complexation improved mefloquine's solubility, potentially impacting its bioavailability.

Identifiants

pubmed: 38140134
pii: pharmaceutics15122794
doi: 10.3390/pharmaceutics15122794
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Amaury Durand (A)

AGIR UR 4294, UFR de Pharmacie, Université de Picardie Jules Verne, 80037 Amiens, France.
Pharmacie à Usage Intérieur, Centre Hospitalier Universitaire d'Amiens-Picardie, 80054 Amiens, France.

David Mathiron (D)

Plateforme Analytique, Université de Picardie Jules Verne, 80039 Amiens, France.

Sébastien Rigaud (S)

LG2A UR 7378, UFR des Sciences, Université de Picardie Jules Verne, 80039 Amiens, France.

Florence Djedaini-Pilard (F)

LG2A UR 7378, UFR des Sciences, Université de Picardie Jules Verne, 80039 Amiens, France.

Frédéric Marçon (F)

AGIR UR 4294, UFR de Pharmacie, Université de Picardie Jules Verne, 80037 Amiens, France.
Pharmacie à Usage Intérieur, Centre Hospitalier Universitaire d'Amiens-Picardie, 80054 Amiens, France.

Classifications MeSH